On April 2, 2024, XTL Biopharmaceuticals Ltd. confirmed it has regained compliance with Nasdaq's minimum bid price requirement after maintaining a share price over $1.00 for 10 consecutive days, following a previous notice on October 18, 2023. This event is significant for the company as it ensures continued listing on Nasdaq.